FSD Pharma Says Arbitration Panel Finds That Syneos Health Failed To Use Commercially Reasonable Efforts In Conducting Trial For FSD 201
Portfolio Pulse from Benzinga Newsdesk
FSD Pharma has announced that an arbitration panel found Syneos Health to have failed in using commercially reasonable efforts in conducting a trial for FSD 201.
July 17, 2023 | 9:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FSD Pharma's trial for FSD 201 was found to have been conducted without reasonable efforts by Syneos Health, according to an arbitration panel.
The arbitration panel's decision is in favor of FSD Pharma, which could potentially lead to a positive impact on the company's reputation and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Syneos Health was found by an arbitration panel to have failed in using commercially reasonable efforts in conducting a trial for FSD 201.
The arbitration panel's decision against Syneos Health could potentially harm the company's reputation and negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100